Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor of neurology, Albert Einstein College of Medicine, addresses the treatment of narcolepsy in recent years.
There are several features of narcolepsy that are considered when prescribing treatment, with sodium oxybate currently serving as a first-line treatment in these patient populations, said Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor of neurology, Albert Einstein College of Medicine.
Transcript
Can you speak on current methods of treatment for narcolepsy-related excessive daytime sleepiness and factors considered when prescribing treatment?
For the treatment of narcolepsy, we have quite a large number of medications. There have been a number of new medications that have been approved recently. Traditionally, we had the stimulants, such as amphetamines and methylphenidate, and these are largely sort of going away, as we have drugs and medications that are more specific for the treatment of narcolepsy.
There are many features to narcolepsy, such as excessive daytime sleepiness, abnormal REM [rapid-eye movement] phenomena, and disturbed nocturnal sleep. And the medications that are being used in narcolepsy have targeted either 1 or more of these particular symptoms. Most of the medications that have been used in the past have targeted the excessive daytime sleepiness component of narcolepsy, so they would be more alerting or wake-promoting medications.
With the development of sodium oxybate back in 2000, we really saw medication that could treat all symptoms of narcolepsy. So we could treat the nocturnal sleep disturbance that we typically see in narcolepsy, the excessive daytime sleepiness, and the abnormal REM phenomena, particularly cataplexy. So, oxybate has become really a first-line treatment for patients with narcolepsy.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen